IV Iron Replacement for Anemia
Recruiting1 awardPhase 2
Philadelphia, Pennsylvania
This trial is testing if giving iron through an IV can help cancer patients who are getting chemotherapy before surgery. The goal is to improve their blood health and reduce the need for blood transfusions. Intravenous iron therapy has been shown to be advantageous in treating anemia and reducing the need for blood transfusions in cancer patients.
Popular Filters
Trials for Myelodysplastic Syndrome Patients
Luspatercept for Myelofibrosis
Recruiting1 awardPhase 3
Birmingham, Alabama
This trial is studying how well luspatercept works in treating patients with myeloproliferative neoplasm-associated myelofibrosis and anemia who are on concomitant Janus kinase 2 inhibitor therapy and who require red blood cell count transfusions.
Chemotherapy
INCB000928 + Ruxolitinib for Myelofibrosis
Recruiting1 awardPhase 1 & 2
Duarte, California
This trial is testing a new drug called INCB000928, either alone or with ruxolitinib, to see if it is safe and effective. It targets people with Myelofibrosis who need regular blood transfusions or have severe anemia. The goal is to see if the drug can reduce the need for transfusions and improve anemia symptoms.
Trials for Sickle Cell Disease Patients
Luspatercept for Myelofibrosis
Recruiting1 awardPhase 3
Birmingham, Alabama
This trial is studying how well luspatercept works in treating patients with myeloproliferative neoplasm-associated myelofibrosis and anemia who are on concomitant Janus kinase 2 inhibitor therapy and who require red blood cell count transfusions.
Chemotherapy
INCB000928 + Ruxolitinib for Myelofibrosis
Recruiting1 awardPhase 1 & 2
Duarte, California
This trial is testing a new drug called INCB000928, either alone or with ruxolitinib, to see if it is safe and effective. It targets people with Myelofibrosis who need regular blood transfusions or have severe anemia. The goal is to see if the drug can reduce the need for transfusions and improve anemia symptoms.
Erythropoiesis-Stimulating Agent
Darbepoetin for High Blood Pressure in Chronic Kidney Disease
Recruiting1 awardPhase 2
Indianapolis, Indiana
This trial is testing whether erythropoietin (EPO) therapy can raise diastolic blood pressure in anemic patients with chronic kidney disease. The study will measure the effects of EPO therapy at 12 weeks after treatment, and will enroll 160 subjects.
Phase 3 Trials
Luspatercept for Myelofibrosis
Recruiting1 awardPhase 3
Birmingham, Alabama
This trial is studying how well luspatercept works in treating patients with myeloproliferative neoplasm-associated myelofibrosis and anemia who are on concomitant Janus kinase 2 inhibitor therapy and who require red blood cell count transfusions.
Pathogen Reduction System
INTERCEPT Blood System for Blood Transfusion Safety
Recruiting2 awardsPhase 3
New Haven, Connecticut
This trial is designed to study the safety and efficacy of the INTERCEPT Blood System for pathogen reduction of red blood cells in comparison to conventional methods. If successful, the system may be made available in areas where transfusion-transmissible infections are common.
Trials With No Placebo
Chemotherapy
INCB000928 + Ruxolitinib for Myelofibrosis
Recruiting1 awardPhase 1 & 2
Duarte, California
This trial is testing a new drug called INCB000928, either alone or with ruxolitinib, to see if it is safe and effective. It targets people with Myelofibrosis who need regular blood transfusions or have severe anemia. The goal is to see if the drug can reduce the need for transfusions and improve anemia symptoms.
Erythropoiesis-Stimulating Agent
Darbepoetin for High Blood Pressure in Chronic Kidney Disease
Recruiting1 awardPhase 2
Indianapolis, Indiana
This trial is testing whether erythropoietin (EPO) therapy can raise diastolic blood pressure in anemic patients with chronic kidney disease. The study will measure the effects of EPO therapy at 12 weeks after treatment, and will enroll 160 subjects.
Pathogen Reduction System
INTERCEPT Blood System for Blood Transfusion Safety
Recruiting2 awardsPhase 3
New Haven, Connecticut
This trial is designed to study the safety and efficacy of the INTERCEPT Blood System for pathogen reduction of red blood cells in comparison to conventional methods. If successful, the system may be made available in areas where transfusion-transmissible infections are common.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.